"I enjoy working with my patients and empowering them to make positive changes.  Together we can discover the cause of hypertension and develop an effective strategy to control it.

I believe that working as a team enhances patient health and the ability to make the lifestyle changes such as diet and exercise."

- Dr. Steigerwalt

Joined the SCSP Team: 2000

Certification
I am certified by the American Board of Internal Medicine and its subspecialty board of Nephrology. I am also certified by the American Society of Hypertension as a Clinical Hypertension Specialist.

Education
My medical degree is from University of Michigan Medical School. I completed my Internal Medicine residency at Detroit General Hospital and my Nephrology Fellowship at Wayne State University and Henry Ford Hospital.

My Interests:

• Resistant Hypertension
• Secondary Hypertension including Renovascular and Primary Aldosteronism
• 24-hour ABPM
• Research: Improved Adherence to Hypertension Regimens in Women
• Research: Progression of Chronic Kidney Disease

Professional Affiliations:

• Past President, Board Member, Physicians for a National Health Program
• American Society of Nephrology
• International Society of Nephrology
• Renal Physicians Association
• International Society for the Study of Hypertension in Blacks
• American College of Physicians
• American Society of Hypertension
• American Heart Association

Hospitals:

• St. John Hospital and Medical Center
• St. John Providence Hospital
• St. John North Shores
• Bostford Hospital
• Henry Ford Cottage
• Select Specialty - Grosse Pointe
• Triumph Hospital - Detroit
• William Beaumont - Royal Oak
  
• William Beaumont - Grosse Pointe

Video Feature:

   National Health Insurance: Real Universal Healthcare
   Stream this Video (Windows Media)

• Blood Pressure - The complete scoop for CKD patients

• Role of Aldosterone in Left Ventricular Hypertrophy among African-American Patients with End-Stage Renal Disease on Hemodialysis
  
  [View listing on Karger.com]
  Steigerwalt, S., Zafar, A., Mesiha, N., Gardin, J., Provenzano, R., Role of Aldosterone in Left Ventricular Hypertrophy among African-American Patients with End-Stage Renal Disease on Hemodialysis, American Journal of Nephrology 2007; 27:159-163.
  ABSTRACT: Recently, serum aldosterone levels have been reported to play a significant role in cardiac hypertrophy. One study of Japanese patients correlated aldosterone levels with the degree of left ventricular hypertrophy (LVH) in those undergoing hemodialysis. However, the role of aldosterone in LVH in non-Japanese patients with end-stage renal disease (ESRD) has not been established. 
• The Prevalence of Primary Aldosteronism in Diabetic Patients
  
  [Full text available on Oxford Journals]
  Jefic, D., Mohiuddin, N., Alsabbagh, R., Fadanelli, M., Steigerwalt, S., The Prevalence of Primary Aldosteronism in Diabetic Patients, The Journal of Clinical Hypertension, Vol. 8, No. 4, pp. 1-4, April, 2006.
  EXCERPT: Although primary aldosteronism (PA) has long been considered a rare cause of hypertension, recent reports suggest that the prevalence of PA among hypertensive patients may exceed 10%
• Comparison of Quality-of-Hypertension-Care Indicators for Groups Treated by Physician Versus Groups Treated by Physician-Nurse Team
  
  [View this article on MedScape.com via Google search]
  Scisney-Matlock, M., Makos, G., Saunders, T., Jackson, F., Steigerwalt, S., Comparison of Quality-of-Hypertension-Care Indicators for Groups Treated by Physician Versus Groups Treated by Physician-Nurse Team, Journal of the American Academy of Nurse Practitioners, Vol. 16, No. 1, January, 2004.
  FROM THE ARTICLE: Epidemiologic studies show that hypertension (HTN), which can lead to arteriosclerosis, cerebrovascular disease, coronary disease, and end-stage renal disease, places a disproportionate burden of mortality and morbidity on African Americans, with African American women in particular having the highest incidence.
• The Effect of Chronic Kidney Disease (CKD) on the Levels of Plasma and Urinary Aldosterone.
  
  Steigerwalt, S., Babbar, N., The Effect of Chronic Kidney Disease (CKD) on the Levels of Plasma and Urinary Aldosterone. The American Society of Hypertension Twenty-Second Annual Scientific Meeting & Exposition, Chicago, IL, 2007.
• Use of Aldosterone Antagonists (AA) Are Associated with Achieved Blood Pressure (BP) Control in Chronic Kidney Disease (CKD)
  
  Topf, J., Steigerwalt, S., Provenzano, R., Use of Aldosterone Antagonists (AA) Are Associated with Achieved Blood Pressure (BP) Control in Chronic Kidney Disease (CKD). American Society of Nephrology 39th Annual Meeting, San Diego, CA, 2006.
• Blood Pressure (BP) Control by Race, Gender and Chronic Kidney Disease (CKD) Stage in a CKD Clinic
  
  Topf, J., Steigerwalt, S., Provenzano, R., Blood Pressure (BP) Control by Race, Gender and Chronic Kidney Disease (CKD) Stage in a CKD Clinic, American Society of Hypertension 21st Annual Scientific Meeting, New York, NY, 2006.
• Preference for Information and Blood Pressure Control Status Influence Blood Pressure Reductions in Women,
  
  Steigerwalt, S., Makos, G., Scisney-Matlock, M., Preference for Information and Blood Pressure Control Status Influence Blood Pressure Reductions in Women, American Society of Hypertension 21st Annual Scientific Meeting, New York, NY, 2006.
• Aldosterone Antagonists (AA) Are Associated with Achieved Target Blood Pressure in Chronic Kidney Disease (CKD)
  
  Topf, J., Steigerwalt, S., Aldosterone Antagonists (AA) Are Associated with Achieved Target Blood Pressure in Chronic Kidney Disease (CKD).  National Kidney Foundation Spring Clinical Meeting, Chicago, IL, 2006.
• Positional Differences in Blood Pressure (BP) in Women
  
  Babbar, N., Steigerwalt, S., Positional Differences in Blood Pressure (BP) in Women. American Society of Hypertension 20th Annual Meeting, San Francisco, CA, 2005.
• Adequacy of Blood Pressure Management in our Hypertensive Type 2 Diabetic Outpatient Population
  
  Abboud, J., Castillo, V., Steigerwalt, S., Adequacy of Blood Pressure Management in our Hypertensive Type 2 Diabetic Outpatient Population. American Society of Hypertension 20th Annual Meeting, San Francisco, CA, 2005.
• Do Cognitive Representations of Medication Behaviors Modify the Impact of Interventions for Blood Pressure Reduction in Women?
  
  Steigerwalt, S., Scisney-Matlock, M., Do Cognitive Representations of Medication Behaviors Modify the Impact of Interventions for Blood Pressure Reduction in Women?  American Society of Hypertension 20th Annual Meeting, San Francisco, CA, 2005.
• The Role of Home Blood Pressure Monitoring (HBPM) in the Control of Hypertension in Renal Transplant Recipients
  
  Awosika, B., Makos, G., Steigerwalt, S., El-Ghoroury, M., Provenzano, R., The Role of Home Blood Pressure Monitoring (HBPM) in the Control of Hypertension in Renal Transplant Recipients. American Society of Transplantation, Boston, MA, 2004.
• Low Prevalence of Primary Aldosteronism in Hypertensive Diabetics
  
  Jefic, D., Al-Sabbagh, R., Fadanelli, M., Steigerwalt, S., Low Prevalence of Primary Aldosteronism in Hypertensive Diabetics. American Society of Hypertension 19th Scientific Meeting , New York, NY, May 2004.
• The Dinamap Dilemma: Inaccuracy of the Commonly used Dinamap 8100 Compared to Simultaneous Mercury Manometer Measurement in Hospitalized Patients at Different Levels of Blood Pressure
  
  Parker, S., Steigerwalt, S., The Dinamap Dilemma: Inaccuracy of the Commonly used Dinamap 8100 Compared to Simultaneous Mercury Manometer Measurement in Hospitalized Patients at Different Levels of Blood Pressure.  American Society of Hypertension, New York NY, 2004.
• Low Prevalence of Primary Aldosteronism in Hypertensive Diabetics
  
  Jefic, D., Al-Sabbagh, R., Fadanelli, M., Steigerwalt, S., Low Prevalence of Primary Aldosteronism in Hypertensive Diabetics. American Society of Hypertension, New York, NY, 2004.
• Spironolactone Use Does Not Increase Serum Potassium in End Stage Renal Disease Patients on Hemodialysis.
  
  Reddy, P., Steigerwalt, S., Brar, B., Provenzano, R., Spironolactone Use Does Not Increase Serum Potassium in End Stage Renal Disease Patients on Hemodialysis.  American Society of Nephrology, San Diego, CA, 2003.
• Aldosterone Is Involved in Left Ventricular Hypertrophy in African American Males with End Stage Renal Disease Treated with Hemodialysis
  
  Steigerwalt, S., Mesiha, N., Zafar, A., Gardin, J., Provenzano, R.,  Aldosterone Is Involved in Left Ventricular Hypertrophy in African American Males with End Stage Renal Disease Treated with Hemodialysis.  American Society of Nephrology, San Diego, CA, 2003.
• Comparison of Quality-of-Hypertension-Care Indicators for Groups Treated by Physician Versus Groups Treated by Physician-Nurse Team
  
  Journal of the American Academy of Nurse Practitioners, Vol. 16 Issue 1 Page 18 January 2004.